References
- Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases.] Neurol Neurosurg Psychiatry 1992; 55: 181–184
- Scherfler C, Schwarz J, Antonini A, et al. Role of DAT-SPECT in the diagnostic work up of Parkinsonism. MovDisord 2007; 22: 1229-1238
- Amenta F, Ricci A, Tayebati SK, et al. The peripheral dopaminergic system: Morphological analysis, functional and clinical applica-tions. ltal J Anat Embryol 2002; 107: 145–167
- Caronti B, Tanda G, Colosimo C, et al. Reduced dopamine in peripheral blood lymphocytes in Parkinson's disease. Neuroreport 1999; 10: 2907–2910
- Caronti B, Antonini G, Calderaro C, et al. Dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson's disease. J Neural Transm 2001; 108: 803–807
- Pell icano C, Buttarelli FR, Circella A, et al. Dopamine transporter immunoreactivity in peripheral blood lymphocytes discriminates Parkinson's disease from essential tremor. J Neural Transm 2007; 114: 935–938
- Benamer TS, Patterson J, Grosset DG, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of 112311-FP-CIT-SPECT imaging: The 112311-FP-CIT-Study Group. Mov Disord 2000; 15: 503–510
- Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001; 57: 1497–1499
- Booij J, Tissingh G, Boer GJ, et al. [1231]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 62: 133–140
- Brooks DJ, Frey KA, Marek KL, et al. Assessment of neuroimaging techniques as biomarkers of progression of Parkinson's disease. Exp Neurol 2003; 184 (Suppl. 1): S78—S89
- Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003; 54: 93–101
- Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287: 1653-1661
- Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498–2508
- Bannon MJ, Whitty CJ. Age-related and regional differences in dopamine transporter mRNA expression in human midbrain. Neurology 1997; 48: 969–977
- Uhl GR. Hypothesis: The role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease. Ann Neurol 1998; 43: 555–560
- Barroso N, Campos Y, Huertas R, et al. Respiratory chain enzyme activities in lymphocytes from untreated patients with Parkinson's disease. Clin Chem 1993; 39: 667–669
- Migliore L, Scarpato R, Coppede F, et al. Chromosome and oxidative damage biomarkers in lymphocytes of Parkinson's disease patients. Int J Environ Health 2001; 204: 61–66
- Petrozzi L, Lucetti C, Gambaccini G, et al. Cytogenetic analysis of oxidative damage in lymphocytes of Parkinson's disease patients. Neurol Sci 2001; 22: 83–84
- Migliore L, Petrozzi L, Lucetti C, et al. Oxidative damage and cytogenetic analysis of leukocytes of Parkinson's disease patients. Neurology 2002; 58: 809–815
- Petrozzi L, Lucetti C, Scarpato R, et al. Cytogenetic alterations in lymphocytes of Alzheimer's disease and Parkinson's disease patients. Neurol Sci 2002; 23: S97—S98
- Jimenez Del Rio M, Velz-Pardo C. 17 Beta-estradiol protects lymphocytes against dopamine and iron-induced apoptosis by a genomic-independent mechanism. Implication for Parkinson's disease. Gen Pharmacol 2000; 35: 1–9
- Blandini F, Mangiagalli A, Cosentino M, et al. Peripheral markers of apoptosis in Parkinson's disease: The effects of dopaminergic drugs. Ann NY Acad Sci 2003; 1010: 675–678
- Blandini F, Cosentino M, Mangiagalli A, et al. Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson's disease. The effects of dopaminergic treatment. J Neural Transm 2004; 111: 1017–1030
- Blandini F, Sinforiani E, Pacchetti C, et al. Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease. Neurology 2006; 66: 529–534
- Kim S, Jeon BS, Heo C, etal. Alpha-synuclein induces apoptosis by altered expression in human peripheral lymphocyte in Parkinson's disease. FASEB 12004; 18: 1615-1617
- Battisti C, Formichi P, Radi E, et al. Oxidative stress-induced apoptosis in PBLs of two patients with Parkinson's disease secondary to alpha-synuclein mutation. I Neurol Sci 2008; 267: 120–124